Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BV100 in Renal Impairment
NCT05086107Phase 1Completed
- Sponsor
- BioVersys AG
- Start
- Oct 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BV100 in Acinetobacter baumannii infection (6 arms), sponsored by BioVersys AG. Primary endpoints: Pharmacokinetics of rifabutin at 96 hours and Single dose pharmacokinetic profile of rifabutin at 96 hours. Started Oct 2021; status: completed.
02
Drugs
BV100
03
Conditions
Acinetobacter baumannii infection
Beyond the preview
Go deeper on NCT05086107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05086107.